BerandaC2RS34 • BVMF
add
CRISPR Therapeutics AG
Tutup sebelumnya
R$27,18
Rentang tahun
R$22,48 - R$43,00
Kapitalisasi pasar
3,23 M USD
Volume Rata-Rata
188,00
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 35,69 jt | -82,26% |
Biaya operasional | 18,12 jt | 9,98% |
Laba bersih | -37,31 jt | -141,76% |
Margin laba bersih | -104,54 | -335,40% |
Penghasilan per saham | -0,44 | -140,00% |
EBITDA | -59,75 jt | -180,21% |
Tarif pajak efektif | -1,91% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,90 M | 12,41% |
Total aset | 2,24 M | 0,56% |
Total liabilitas | 309,95 jt | -10,62% |
Total ekuitas | 1,93 M | — |
Saham yang beredar | 85,77 jt | — |
Harga terhadap nilai buku | 1,21 | — |
Tingkat pengembalian aset | -7,18% | — |
Tingkat pengembalian modal | -7,47% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -37,31 jt | -141,76% |
Kas dari operasi | -50,03 jt | 47,92% |
Kas dari investasi | 105,83 jt | 229,93% |
Kas dari pembiayaan | 16,88 jt | -56,66% |
Perubahan kas bersih | 72,59 jt | 152,40% |
Arus kas bebas | -41,33 jt | 68,36% |
Tentang
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Didirikan
2013
Kantor pusat
Situs
Karyawan
393
